Human Cancer Model Initiative Derivation and Characterization of 665 3D Organoids

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Nature https://doi.org/10.1038/s41586-026-10806-y 
Dr. Dina ElHarouni  et al.

Points

International researchers developed 665 next-generation patient-derived 3D organoid models representing 25 distinct cancer types using biospecimens provided by 2,780 individual donors.
Genomic evaluations of 421 matched tumor-model pairs demonstrated high biological fidelity with 97.8 percent genetic concordance and 95 percent epigenetic concordance.
The public biobank includes 522 models paired with detailed clinical data along with 153 models representing rare cancers and 71 from underrepresented populations.
Molecular sequencing confirmed that derived organoids retain extrachromosomal DNA and post-treatment mutational signatures associated with clinical drug resistance.
Researchers can utilize these expandable and cryopreservable models to accelerate high-throughput drug screening and develop targeted precision oncology interventions.

Summary

This study evaluated the establishment and genomic fidelity of a global biobank created through the Human Cancer Model Initiative (HCMI). Coordinated by international research consortia, including Cold Spring Harbor Laboratory and Northwell Health, the effort addressed the structural limitations of traditional 2D cancer cell lines and xenografts. The initiative generated 665 next-generation 3D organoid models from 2,780 donors across 25 distinct cancer types, establishing a biobank to support preclinical drug screening and personalized oncology.

Multimodal molecular profiling of 421 matched tumor-model pairs evaluated genetic, epigenetic, transcriptomic, and single-nucleus RNA sequencing concordance across long-term passage. Comparative genomic analyses demonstrated 97.8% genetic concordance and 95% epigenetic concordance between original patient tumors and derived organoids. The compendium includes 522 models paired with comprehensive clinical data, 153 models representing rare malignancies (accounting for 23% of successful derivations), 71 models from non-European ancestries, and 43 pediatric or adolescent tumor derivations.

Functional validations confirmed that these 3D organoid systems preserve critical molecular drivers, including extrachromosomal DNA structures and post-treatment mutational signatures associated with therapeutic resistance. The findings demonstrate that patient-derived organoid models maintain long-term biological fidelity, providing an expandable, cryopreservable platform for high-throughput pharmacological screening and translational oncology research.

Link to the article: https://www.nature.com/articles/s41586-026-10806-y

References

ElHarouni, D., Al-Jazrawe, M., Choi, S., Dede, M., Hinoue, T., Misek, S. A., Noh, H., Zanella, L., Tseng, Y.-Y., Francies, H. E., Plenker, D., Kyi, C. W., Perez-Mayoral, J., Stine, M. J., Tonsing-Carter, E., Agarwal, R., Zenklusen, J. C., Clinton, J. M., Shelton, J. M., … Boehm, J. S. (2026). A compendium of next-generation patient-derived models for diverse cancers. Nature, 1–14. https://doi.org/10.1038/s41586-026-10806-y